LEAD ADJUVANT PROBE AS A DUAL TECHNOLOGICAL TOOL TO ADVANCE NEXT-GENERATION VACCINE DEVELOPMENT

The goal of ADJUPROBE is to build upon a major discovery made within the ERC-2016-STG-716878 project to validate and valorise our dual synthetic technological tool, moving it forward to boost vaccine efficacy from technical development to commercialisation.

We will exploit our lead adjuvant in further preclinical settings in terms of scaled-up production, functional validation, and additional vaccine trials in mice with clinically relevant antigens.

In parallel, we will confirm and advance the innovation of our technology towards commercial exploitation by implementing a multifaceted valorisation plan supporting the technical development.

The plan includes consolidation of intellectual property (IP) rights and IP position, engagement of pharma/biotech partners and investors, as well as verification of the potential of spin-off creation.

Our adjuvant technology based on a scalable semi-synthetic saponin has demonstrated its potential as a dual tool with superior performance to the approved, natural QS-21 adjuvant.

These breakthroughs have been provisionally protected via a priority patent application and have also attracted the interest of important biotech/pharma companies.

ADJUPROBE will provide decisive proof-of-concept for preclinical development and validation of our technological tool, including synthesis upscaling and confirmation of the superiority of our adjuvant lead in disease-related vaccines benchmarked against QS-21.

Moreover, key valorisation outcomes based on successful implementation of our transference and commercialisation plan, such as advancing IPR protection and spin-off creation together with fruitful pharma and investor partnerships, will facilitate market entry and traction for ADJUPROBE in the near future.